FLNA — FILANA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1069530 ·
Last close
$0.48
Market Cap
$24.19M
52W High
$3.45
52W Low
$0.39
ADV30
427,433
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -11,274,000 | -10,726,000 | 100,058,000 | 46,990,000 | 42,082,000 |
| Jun 2026 | 0 | — | -9,393,000 | -8,603,000 | 103,903,000 | 82,681,000 | 40,294,000 |
| Mar 2026 | 0 | — | -11,168,000 | -10,331,000 | 108,367,000 | 86,573,000 | 40,226,000 |
| Dec 2025 | 0 | — | -14,288,000 | -12,539,000 | 118,355,000 | 95,502,000 | 43,952,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,702,000
Investing CF
$-581,000
Financing CF
$-396,000
CapEx
$-501,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.87
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-515,018,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-46,709,000
Pretax Income TTM
$-42,280,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -96,126,000 | -90,973,000 | 118,355,000 | 43,952,000 | 74,403,000 | -32,252,000 |
| Dec 2024 | 0 | -142,279,000 | -24,342,000 | 157,533,000 | 11,829,000 | 145,704,000 | -116,929,000 |
| Dec 2023 | 0 | -107,333,000 | -97,217,000 | 151,663,000 | 14,195,000 | 137,468,000 | -82,025,000 |
| Dec 2022 | 0 | -81,482,000 | -76,246,000 | 234,834,000 | 7,295,000 | 227,539,000 | -77,514,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-42,280,000
OpCashFlow TTM
—
Assets (Latest)
$103,903,000
Forward EPS
—
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.55 · call volume: 2 · put volume: 808
Expected Move to 2028-01-21:
±$0.45
(81.82%) —
implied range
$0.10 –
$1.00
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLCS | Cell Source, Inc. | $25.14M | $0.37 | — |
| AARD | Aardvark Therapeutics, Inc. | $25.17M | $1.15 | — |
| ETST | Earth Science Tech, Inc. | $23.17M | $0.08 | — |
| BIOE | Bio Essence Corp | $25.29M | $0.47 | — |
| ABVC | ABVC BIOPHARMA, INC. | $25.36M | $0.94 | — |
News headlines (Yahoo Finance, 1h cache)
Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board
2026-11-11 13:00 · Yahoo
Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
2026-11-05 13:00 · Yahoo
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
2026-10-28 12:00 · Yahoo
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
2026-10-09 12:00 · Yahoo
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
2026-09-22 12:00 · Yahoo
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
2026-07-29 12:00 · Yahoo
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
2026-05-07 12:00 · Yahoo
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
2026-05-05 12:00 · Yahoo
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
2026-04-15 12:00 · Yahoo
Data I/O And 2 Other Promising Penny Stocks To Watch
2026-05-29 18:05 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-18 16:13:24 | 2026-11-16 | Barry Richard | Pres, CEO | P - Purchase | 0.47 | 440206 | 206897 |
| 2026-11-18 16:05:35 | 2026-11-16 | Cook Robert Christopher | COO,Legal Officer | P - Purchase | 0.46 | 121575 | 55925 |